Novartis has welcomed TGA approval of PLUVICTO, the registered radioligand therapy in Australia for the treatment of eligible patients with metastatic castration-resistant prostate cancer. …
TGA approves the first targeted radioligand therapy for advanced prostate cancer
August 22, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 13, 2025 - - Latest News -
New immunisation strategy highlights COVID impact, priority patients and new technologies
June 12, 2025 - - Latest News -
Medicines Australia establishes radiopharmaceuticals working group
June 12, 2025 - - Latest News -
MSD Australia and New Zealand certified a 'Great Place to Work'
June 12, 2025 - - Latest News -
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 12, 2025 - - Latest News -
Novo Nordisk partners with Heart of Australia to expand clinical trial access
June 12, 2025 - - Latest News -
Mark Butler starts the process of NDIS pricing reform
June 11, 2025 - - Latest News